PATENT CLAIM ANALYSIS

Application Number: 15951848
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "056000"]

Abstract:
The present invention relates to the use of heparin derivatives for the prevention and/or treatment of cancer and/or cancer metastasis. The heparin derivatives are substantially 2-O and/or 6-O desulphated heparins which function as inhibitors of galectin-3 activity.

Claim (Index 24):
A method according to  claim 16 , wherein the heparin derivative has the general structural formula I shown below: wherein: R 1  and R 2  are selected from hydrogen or sulphate, with the proviso that either:\n (i) substantially all of the R 1  groups present in the molecule are hydrogen when substantially all (e.g. >70%) of the R 2  groups present are sulphate; \n (ii) substantially all of the R 2  groups present in the molecule are hydrogen when substantially all (e.g. >70%) of the R 1  groups present are sulphate, or \n (iii) substantially all of the R 1  and R 2  groups present in the molecule are hydrogen; \n n is 1 to 30; R 3  is selected from sulphate, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted acyl, substituted or unsubstituted amido and phosphate; R 4 is selected from the group consisting of hydrogen, substituted or unsubstituted (1-6C)alkyl, substituted or unsubstituted aryl; R 5  and R 6  are each separately selected from the group consisting of hydrogen, sulphate, phosphate, substituted or unsubstituted (1-6C)alkyl, substituted or unsubstituted (1-6C)alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted aryloxy, substituted or unsubstituted acyl, and substituted or unsubstituted amido; and R 7  and R 8  are each separately selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted acyl, a terminal monosaccharide group, a terminal disaccharide group and/or fragments or derivatives thereof; or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 91.0
- Lexical Diversity: 1.34483
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14440005', '11882978', '11314736', '12227630', '13304292']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8178903311943718
- 35 USC 102 Novelty (BERT): 0.5262150763196786
- Combined Prediction Score: 0.7887228057069025
- Mean Citation Score: 281.08527999999995
- Max Citation Score: 341.1478600000001
- Similarity Product: 225.04946035085328

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test